ArticleHaematologica2026
Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied platelet recovery in 93 patients with myelofibrosis, following an allogeneic hemopoietic stem cell transplant (HSCT). The primary end point of the study was achieving a platelet count of 50x109/L within day +100 post transplant, which occurred in 62 patients (67%), predicted 5-year non-relapse mortality (NRM) (5% vs. 55%, P=0.0009) and 5-year actuarial survival (85% vs. 38%, P<0.00001); relapse was unaffected. The cumulative incidence of strong platelet recovery was predicted by a matched sibling donor (MSD) compared to alternative donors (90% vs. 60%, P=0.001), by the dose of CD34+ cells (cut off 8.68x106/kg; 83% vs. 61%, P=0.01), recipient age (cut off 63 years; 72% vs. 48%, P=0.01), and splenectomy (86% vs. 63%, P=0.04). In multivariate Cox analysis, significant predictors of platelet recovery were a MSD (P=0.003), a high CD34 cell dose (P=0.02), splenectomy (P=0.003), and younger patient age (P=0.02). Patients with slow platelet recovery have significantly lower platelet counts long term, combined with chronic graft-versus-host disease. In conclusion, strong post-HSCT platelet recovery in MF patients is mainly predicted by donor type, together with CD34 cell dose and patient age, and is strongly associated with NRM and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.